|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06BA09
|
|
gptkbp:availableOn
|
gptkb:tablet
capsule
|
|
gptkbp:chemicalFormula
|
gptkb:C17H21NO
|
|
gptkbp:compatibleWith
|
stimulant
|
|
gptkbp:contraindication
|
severe cardiovascular disorders
narrow angle glaucoma
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:drugClass
|
norepinephrine reuptake inhibitor
|
|
gptkbp:eliminationHalfLife
|
5.2 hours
21.6 hours (poor metabolizers)
|
|
gptkbp:genericName
|
gptkb:atomoxetine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Strattera
|
|
gptkbp:interactsWith
|
gptkb:MAO_inhibitors
gptkb:albuterol
CYP2D6 inhibitors
vasopressors
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketedAs
|
gptkb:Strattera
2002
Attentin
Tomoxetin
|
|
gptkbp:mechanismOfAction
|
selective norepinephrine reuptake inhibition
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notControlledSubstance
|
gptkb:United_States
|
|
gptkbp:overdoseSymptoms
|
hypertension
tachycardia
agitation
somnolence
hyperactivity
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adolescents
adults
children
|
|
gptkbp:riskFactor
|
suicidal ideation (in children and adolescents)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
increased heart rate
insomnia
dry mouth
decreased appetite
increased blood pressure
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
|
|
gptkbp:bfsParent
|
gptkb:atomoxetine
|
|
gptkbp:bfsLayer
|
7
|